Role of Promyelocytic Leukemia (Pml) Sumolation in Nuclear Body Formation, 11s Proteasome Recruitment, and as2O3-Induced Pml or Pml/Retinoic Acid Receptor α Degradation by Lallemand-Breitenbach, Valérie et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2001/06/1361/11 $5.00
Volume 193, Number 12, June 18, 2001 1361–1371
http://www.jem.org/cgi/content/full/193/12/1361
 
1361
 
Role of Promyelocytic Leukemia (PML) Sumolation 
in Nuclear Body Formation, 11S Proteasome 
 
Recruitment, and As
 
2
 
O
 
3
 
-induced PML or 
PML/Retinoic Acid Receptor
 
  
 
 Degradation
 
By Valérie Lallemand-Breitenbach,
 
*
 
 Jun Zhu,
 
* 
 
Francine Puvion,
 
‡
 
 
Marcel Koken,
 
*
 
 Nicole Honoré,
 
* 
 
Alexandre Doubeikovsky,
 
*
 
Estelle Duprez,
 
§
 
 Pier Paolo Pandolﬁ,
 
 
 
 Edmond Puvion,
 
‡
 
Paul Freemont,
 
§
 
 and Hugues de Thé
 
*
 
From the 
 
*
 
Centre National de la Recherche Scientiﬁque (CNRS) UPR 9051, Laboratoire Associé 
N°11 du Comité de Paris de la Ligue Nationale Contre le Cancer, Afﬁlié à l’Université Paris VII, 
 
Hôpital St. Louis 1, 75475 Paris Cedex 10, France; the 
 
‡
 
CNRS UPR 9044, BP 8 Institut de 
Recherche sur le Cancer, 94801 Villejuif, France; the 
 
§
 
Molecular Structure and Function Laboratory, 
 
Imperial Cancer Research Fund, WC2A3PX London, United Kingdom; and the 
 
 
 
Department of 
Human Genetics and Molecular Biology Program, Memorial Sloan Kettering Cancer Center,
New York, New York 10021
 
Abstract
 
Promyelocytic leukemia (PML) is the organizer of nuclear matrix domains, PML nuclear bodies
(NBs), with a proposed role in apoptosis control. In acute promyelocytic leukemia, PML/retin-
 
oic acid receptor (RAR) 
 
 
 
 expression disrupts NBs, but therapies such as retinoic acid or arsenic
 
trioxide (As
 
2
 
O
 
3
 
) restore them. PML is conjugated by the ubiquitin-related peptide SUMO-1, a
process enhanced by As
 
2
 
O
 
3
 
 and proposed to target PML to the nuclear matrix. We demonstrate
that As
 
2
 
O
 
3
 
 triggers the proteasome-dependent degradation of PML and PML/RAR
 
 
 
 and that
this process requires a specific sumolation site in PML, K160. PML sumolation is dispensable for
its As
 
2
 
O
 
3
 
-induced matrix targeting and formation of primary nuclear aggregates, but is required
for the formation of secondary shell-like NBs. Interestingly, only these mature NBs harbor 11S
proteasome components, which are further recruited upon As
 
2
 
O
 
3
 
 exposure. Proteasome recruit-
ment by sumolated PML only likely accounts for the failure of PML-K160R to be degraded.
Therefore, studying the basis of As
 
2
 
O
 
3
 
-induced PML/RAR
 
 
 
 degradation we show that PML
sumolation directly or indirectly promotes its catabolism, suggesting that mature NBs could be
sites of intranuclear proteolysis and opening new insights into NB alterations found in viral in-
fections or transformation.
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Introduction
 
The promyelocytic leukemia (PML)
 
1
 
 gene was initially
characterized through its implication in the t(15;17) trans-
location specific for acute promyelocytic leukemia (APL),
which yields a PML/retinoic acid receptor (RAR) 
 
 
 
 fusion
protein (1). A member of the RING-B-box-coiled-coil
(RBCC) protein family, PML contains three zinc finger-
like domains (a RING finger and two B boxes) and a
coiled–coil dimerization domain. Although RBCC pro-
teins have features of molecular adaptors, they have not
been assigned a common function. Yet, the presence of a
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Abbreviations used in this paper:
 
 APL, acute promyelocytic leukemia;
CHO, Chinese hamster ovary; HA, hemagglutinin; LMB, leptomycin B;
MEF, mouse embryo fibroblast; NB, nuclear body; NLS, nuclear local-
ization signal; PML, promyelocytic leukemia; RA, retinoic acid; RAR,
RA receptor; RBCC, RING-B-box-coiled-coil. 
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RING finger could point to an implication in ubiquitin
conjugation (2). PML knockout mice are viable but sus-
ceptible to some infections and tumor development, possi-
bly as the consequence of their apoptosis resistance (3, 4).
Conversely, PML overexpression was shown to induce
growth arrest, apoptosis, or senescence (5–8). PML was
proposed to modulate transcription through a direct inter-
action with CBP, Daxx, and/or another RBCC family
member, TIF1
 
 
 
 (9–12). A number of PML isoforms are
generated through alternative splicing in the 3
 
 
 
 region
mRNA (13).
A fraction of PML is nucleoplasmic, the rest being lo-
cated on discrete subnuclear matrix-associated structures,
the PML nuclear bodies (NBs; 14–18). PML appears to be
the organizer for NBs, targeting proteins such as Sp100,
CBP, or Daxx onto these domains (19, 20). Disruption of
PML NBs has been observed in a variety of disease pro-
cesses such as neurodegenerative disorders, virus infections,
or APL (18). In the latter, PML/RAR
 
 
 
 expression domi-
nantly delocalizes NB-associated proteins towards mi-
crospeckles. Exposure to two therapeutic agents, retinoic
acid (RA) or arsenic trioxide (As
 
2
 
O
 
3
 
), results in the degra-
dation of the PML/RAR
 
 
 
 fusion and accordingly restores
NB structure, linking NBs integrity to disease status. PML
delocalization by PML/RAR
 
 
 
 promotes apoptosis resis-
tance, while NB targeting of PML favors cell death (5, 8).
Similarly, the wild-type PML alleles oppose leukemogene-
sis in PML/RAR
 
 
 
 transgenic mice (21).
PML is covalently modified by SUMO-1, a ubiquitin-
like polypeptide also known as sentrin-1, UBL-1, or PIC-1.
SUMO-1 can be conjugated onto a variety of proteins
including p53, I
 
 
 
B, Sp100, PML, and RanGAP. Like
ubiquitin, SUMO-1 covalently binds lysine residues of tar-
get proteins in an ATP-dependent reaction requiring the
E2-conjugating enzyme UBC9. In the case of RanGAP-1,
the unmodified protein is cytoplasmic, while sumolated
RanGAP-1 binds to the nuclear pore (22). For I
 
 
 
B,
SUMO-1 appears to compete with ubiquitin for modifica-
tion of the same target lysine, inhibiting proteasome-
dependent I
 
 
 
B degradation (23). Thus, SUMO-1 seems to
modulate the conformation of its target proteins rather than
induce their degradation. Three major sites of SUMO-1
modification were identified in PML: K65 in the RING
finger; K160 in the first B-box; and K490 in the nuclear lo-
calization signal (NLS; references 24 and 25). It was strongly
suggested that these modifications, which are rapidly en-
hanced by As
 
2
 
O
 
3
 
, are critical for PML targeting onto the
nuclear matrix and recruitment of NB-associated proteins
(10, 20, 26), which in turn, was suggested to contribute to
apoptosis induction (27) or transcriptional regulation (28).
As
 
2
 
O
 
3
 
-induced PML/RAR
 
 
 
 degradation is the likely ba-
sis of its clinical efficacy in APL. We demonstrate that As
 
2
 
O
 
3
 
induces sumolation and proteasome-dependent degradation
of PML or PML/RAR
 
 
 
. A single SUMO conjugation site
in PML is required for the formation of “mature” shell-like
bodies and proteasome recruitment as well as PML degrada-
tion, providing the first examples of both SUMO-promoted
degradation and NB-associated proteolysis.
 
Materials and Methods
 
Plasmids and Mutagenesis.
 
His tag (C ATG CAT CAC CAC
CAT CAC CAT TC) and SV40-NLS (C ATG GCGCT CCC
AAA AAG AAA AGA AAG GT) annealed oligonucleotides
were cloned into the ATG-NcoI site of PML-pSG5 plasmid.
K-A(65/67) and K-R(487/490) PML mutants were cloned into
His-(NLS)-PML-pSG5 plasmids. COOH-terminal deletions
and mutagenesis were performed on His-(NLS)-PML-pSG5
plasmids using a pfuTurbo DNA polymerase mutagenesis kit
(Stratagene). Wild-type K-R(160), K-R(160/490) (2K), and
K-R(65/160/490) (3K) PML mutants were cloned in pcDNA4
(Invitrogen) for tetracycline inducible PML
 
 
 
/
 
 
 
 cell transfection
and in MSCVneo plasmid for retroviral infections. Ubiquitin
gene was tagged by influenza hemagglutinin (HA) in pSG5
plasmid.
 
Cell Lines, Cell Culture, and Transfections.
 
Cells were cultured
in 10% FCS DMEM media (GIBCO BRL) with an appropriate
selection of G418, hygromycin, zeomycin, and blasticidine.
Transfection assays were performed with fugene 6 liposomes
(Roche). Mouse embryo fibroblasts (MEFs) derived from
PML
 
 
 
/
 
 
 
 animals were immortalized with a plasmid expressing
SV40 large T antigen. A stable cell line expressing PML under
the transcriptional dependence of the Tet-on system (Invitro-
gen) was then derived by successive expression of the hybrid
Tet repressor (pcDNA6/TR) (coupled to blasticidin resistance)
and pcDNA4/PML (coupled to zeocin resistance). A 280-mM
As
 
2
 
O
 
3
 
 stock (Sigma-Aldrich) was prepared by dissolving the
powder in 1 M NaOH, then 1 mM solution was prepared in
Tris-buffered saline. Lactacystin (Affiniti Research Products)
was used at 10 
 
 
 
M overnight, while leptomycin B (LMB) was
used at 2 
 
 
 
M. Recombinant retroviruses expressing PML or
PML/RAR
 
 
 
 were produced by transient transfection of BOSC
packaging cells. Then, filtered supernatant was used for infec-
tion of NIH3T3 cells or PML
 
 
 
/
 
  
 
MEF cells followed by neo-
mycin selection.
 
Antibodies, Western Blot Analysis, Immunofluorescence, and Elec-
tron Microscopy.
 
A mix of 5E10 and PG-M3 (Santa Cruz Bio-
technology, Inc.) monoclonal antibodies was used for immuno-
fluorescence. The monoclonal anti–SUMO-1 antibodies (mouse
monoclonal anti–GMP-1 antibody) was obtained from Zymed
Laboratories, while anti–SUMO-2 was a gift from M. Matunis
(Johns Hopkins University, Baltimore, MD). The monoclonal
anti-Ha used is the clone 16B12 (Babco). The rabbit polyclonal
antibody against proteasome 20S “core” and against 11S regulator
subunit 
 
 
 
 and 
 
  
 
(PA28) are produced by Affiniti Research Prod-
ucts. One anti-Daxx monoclonal antibody was purchased from
Santa Cruz Biotechnology, Inc. (M-112 clone) and the other was
provided by G. Grosveld (St. Jude Children’s Research Hospital,
Memphis, TN). The A-22 anti-CBP polyclonal antibody (Santa
Cruz Biotechnology, Inc.) was used in immunofluorescence assay
and C-20 for Western blot analysis.
For immunofluorescence analysis, cells were fixed in para-
formaldehyde for anti-PML, anti–SUMO, anti-HA, anti-CBP,
anti-Daxx antibodies, and in acetone for anti-proteasome 20S and
11S. Cell extracts were prepared by boiling PBS-washed cells in
Laemmli buffer. Proteins were separated by 8–10% SDS-PAGE,
transferred to nitrocellulose, blocked in 10% milk for 2 h, and
then incubated overnight with the first antibody at 4
 
 
 
C and 1 h
with the second antibody at room temperature. For electron mi-
croscopy, cells were fixed at 4
 
 
 
C in 1.6% glutaraldheyde or 4%
paraformaldehyde for 30 min and then extensively washed in
0.1 M phosphate Sörensen buffer, pH 7.2–7.3. The fixed material
was embedded in Lowricryl K4M as described previously. 
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Immunoprecipitation, His Purification, and Cell Fractionation.
 
His-tagged PML proteins were purified using Talon metal affin-
ity resin (CLONTECH Laboratories, Inc.) in denaturing condi-
tions, as suggested by the manufacturer. For cell fractionation,
cells were lysed in RIPA. After brief sonication and centrifuga-
tion, Laemmli buffer was added to the supernatant (RIPA frac-
tion), and the pellet was washed twice and resuspended by boil-
ing in Laemmli buffer (pellet fraction).
 
Results
 
Arsenic Triggers both SUMO Conjugation and Proteasome-
dependent Degradation of PML within the Nucleus.
 
PML/
RAR
 
 
 
 degradation by As
 
2
 
O
 
3
 
 is dependent on its PML
moiety (29). PML can undergo a variable degree of
SUMO-1 modification (25, 26, 30). We confirm that in
cells stably overexpressing a specific PML isoform (1) at
least three distinct proteins reactive with PML and
SUMO-1, as well as SUMO-2, were found above the 90-
kD parental PML band (Fig. 1 a). A 1-h treatment with
10
 
 
 
6 
 
M As
 
2
 
O
 
3
 
 induce a dramatic shift towards the SUMO
reactive PML proteins, accompanied by a corresponding
decrease in unmodified PML (26, 29). A longer As
 
2
 
O
 
3
 
treatment (8–24 h) of Chinese hamster ovary (CHO) cells,
HeLa, U373, or MEF cells overexpressing PML leads to a
drastic decrease in the total amount of PML proteins. Un-
modified PML disappear and only high molecular mass
SUMO-modified species (
 
 
 
220 kD) remain (Fig. 1 b, and
data not shown). This reflects PML degradation rather than
the inefficient detection of high molecular weight PML–
SUMO complexes because in some experiments the abun-
dance of these complexes also decreases after As
 
2
 
O
 
3
 
 expo-
sure (Figs. 1 c and 2 b, and data not shown). Such loss of
PML can be reversed by the proteasome inhibitors lactacys-
tin (Fig. 1 b) or MG132, neither of which interfere with
 
the sumolation process (data not shown), implicating pro-
teasomes in As
 
2
 
O
 
3
 
-induced PML degradation.
PML and Sp100 genes are primary IFN-inducible target
genes (31). As for the specific PML isoform studied above,
all endogenous PML isoforms expressed in IFN-treated
HeLa cells were degraded upon an overnight As
 
2
 
O
 
3
 
 treat-
ment, while Sp100 was not (Fig. 1 c). Some nuclear pro-
teins are degraded in the cytoplasm. PML has been shown
to undergo exportin 1–mediated export (32). CHO–PML
cells were thus exposed to As
 
2
 
O
 
3
 
 and/or to the nuclear ex-
port inhibitor LMB for 12 h. LMB increased PML NB-
associated fluorescence (data not shown) but did not block
(and even enhanced) As
 
2
 
O
 
3
 
-induced PML degradation
(Fig. 1 d). Therefore, As
 
2
 
O
 
3
 
 treatment triggers PML sumo-
lation coupled to its proteasome-dependent catabolism
within the nucleus.
 
Distinct Isoform-specific Sequences Are Required for As
 
2
 
O
 
3
 
-
triggered PML Degradation.
 
In our working isoform (1),
deletion analysis showed that five repeats of a LASPL motif
(amino acid 594–615), a COOH-terminal sequence, are
required for As
 
2
 
O
 
3
 
-induced degradation
 
 
 
(Fig. 2). Mutants
without these repeats were consistently expressed at a
higher level than the parental protein (Fig. 2 b), suggesting
that this sequence acts as both a constitutive and an As
 
2
 
O
 
3
 
-
dependent degradation signal. The core common to all iso-
forms (PML1-571) is not degraded upon As
 
2
 
O
 
3
 
 exposure
(Fig. 2 b), while all endogenous PML isoforms (Fig. 1 c) or
overexpressed ones (PML-4 [13], Fig. 2 b, and PML-1, -2,
-3 not shown) are degraded. In one of these isoforms a
LASPL repeat is required for PML catabolism, but we have
not pinpointed the residues required for degradation of the
other isoforms. Many RBCC proteins contain specific in-
teraction domains in their COOH terminus (see Discus-
sion). Sensitivity to As
 
2
 
O
 
3-triggered degradation conferred
Figure 1. Arsenic induces SUMO modification and
proteasome-dependant degradation of PML. (a) West-
ern blot analysis of His-purified proteins from His-
PML-CHO cells treated or not with 1  M As2O3 over-
night and revealed with anti-PML antibodies (left), with
anti–SUMO-1 antibodies (middle), or anti–SUMO-2
antibodies (right). (b) Western blot analysis performed
on whole CHO–PML extract revealed with anti-PML
and anti-actin antibodies. Cells were treated overnight
with 1  M As2O3, 10  M lactacystin (L), both (L/As),
or none ( ). SUMO-modified PML species are indi-
cated. (c) HeLa cells were treated for 48 h with IFN- 
or - , with or without an overnight As2O3 treatment.
PML isoforms induced by IFN are degraded after As2O3
treatment (top), whereas Sp100 isoforms are not de-
graded (bottom). (d) PML–CHO cells were treated or
not with 1  M As2O3 and 10 nM LMB for 12 h.1364 Sumolation in NB Formation and PML or PML/RAR  Degradation
by distinct isoform-specific sequences could suggest that
their common function is to interact with proteins in-
volved in PML catabolism.
As2O3-induced Catabolism of PML or PML/RAR  Re-
quires the K160 Sumolation Site. Arsenic promotes both
PML sumolation and its degradation. To address the role of
sumolation in degradation, we mutated the three target
lysines K65, K160, and K490 of PML, yielding the PML-
3K mutant. Since K490 is essential for NLS function (25),
the SV40 NLS was fused to the NH2-terminal end of PML.
No evidence for the formation SUMO-modified PML-3K
could be obtained by Western blots or fluorescence, even
upon As2O3 treatment (Fig. 3 a, and data not shown).
PML-3K was stably expressed either in CHO cells or in
SV40(T)-immortalized PML /  fibroblasts under the tran-
scriptional control of a tetracycline-on promoter. Strik-
ingly, in both systems, As2O3 treatment no longer induced
the degradation of PML-3K (Fig. 3 a). However, a clear
increase in PML-3K expression was observed upon lacta-
cystin exposure (Fig. 3 a), suggesting that these three lysines
are not major ubiquitination sites. Therefore, PML-3K can
still be targeted by the ubiquitin/proteasome system in
contrast to the sumolation mutant of I B .
Mutation of K490 shifted the SUMO ladder towards
lower molecular weights with the loss of a single SUMO
conjugate. Mutation of K65 did not change the pattern of
PML conjugation before or after As2O3 exposure (data not
shown). Since K65 is not part of a SUMO modification
consensus sequence (25), it is unlikely to be a SUMO con-
jugation site. In contrast, when K160 was mutated, a single
SUMO conjugate remained and PML sumolation became
completely As2O3 insensitive (Fig. 3 b). This single sumo-
lated PML protein is modified on K490 since it was lost
upon mutation of this site (data not shown). We conclude
that PML harbors two independent sumolation sites with
distinct properties, with only SUMO conjugation of K160
triggering the formation of higher molecular mass PML ad-
ducts. Then, we examined the effect of an overnight As2O3
exposure (Fig. 3 c). Mutation of K160, but not that of K65
or K490, abolished PML degradation linking the presence
of high molecular weight PML adducts with its catabolism.
Figure 2. The COOH terminal part of PML proteins is required for
their As2O3-induced degradation. (a) Schematic representation of As2O3-
induced degradation of different PML mutants and another isoform
(PML-4). (b) Western blot analysis of some of the mutants depicted above
with or without an overnight 1  M As2O3 treatment. Unsumolated PML
proteins are indicated by arrows. PML mutants were stably expressed in
CHO cells from pSG5 expression vectors.
Figure 3. SUMO modification of K160 is required for As2O3-induced
PML and PML/RAR  degradation. (a) When stably expressed in CHO
cells, PML-3K is not degraded upon an overnight As2O3 (As) exposure
but upregulated by lactacystin (L) treatment. (b) SUMO modification of
K160R and K490R PML mutants stably overexpressed in CHO treated
with 1  M As2O3 for 1 h were analyzed by Western blot analysis. (c) A
longer As2O3 exposure (12 h) induces degradation of wild-type PML and
K490R mutant, but not K160R. (d) Mutation of K160 in PML/RAR 
abolishes As2O3-induced degradation (12-h treatment) in retrovirally
transduced NIH3T3 cells. This Western blot was revealed with an anti-
RAR  antibody.1365 Lallemand-Breitenbach et al.
Ubiquitin could never be detected in these complexes,
even after As2O3 treatment, lactacystin exposure, and ad-
duct purification under denaturing conditions (data not
shown). Moreover, these complexes are highly reactive
with SUMO-1 and -2 suggesting that they may contain
more than two SUMO molecules.
As2O3 induces the degradation of the APL-specific
PML/RAR  oncoprotein (26, 29, 33) in a lactacytin or
MG132 reversible manner (34). To test the hypothesis that
this sumolation site plays a role in PML/RAR  degrada-
tion, we stably expressed in NIH3T3 cells PML/RAR  or
a mutant bearing a K to R mutation on K160 using retro-
viral transfer (Fig. 3 d). Mutation of K160 modified the
sumolation pattern of PML/RAR  and abolished its
As2O3-induced degradation, strongly suggesting that the
molecular mechanisms involved are similar to those out-
lined for PML.
Resistance of PML-3K to As2O3-induced Catabolism Does
Not Reflect Its Inability to be Targeted to the Nuclear Matrix.
Arsenic exposure shifts PML towards the matrix (assessed
by the RIPA insoluble fraction) as early as 1 h (Fig. 4 a,
lane 4; references 26 and 29). After 12 h, only a small
amount of the SUMO-modified PML remains in the ma-
trix as the consequence of As2O3-triggered degradation
(Fig. 4 a, lane 6). Combining lactacystin to As2O3 led to a
sharp increase in the amount of matrix-bound PML (Fig. 4
a, lane 10) consistent with the idea that degradation occurs
on the nuclear matrix.
Since SUMO conjugation of PML was proposed to trig-
ger its matrix association (26), failure of PML-3K to de-
grade may reflect its inability to be matrix targeted. To test
this hypothesis, we analyzed the matrix association of
PML-3K in both CHO and PML /  cells. Upon a 1-h
As2O3 exposure, a sharp transfer was observed from the
RIPA soluble fraction to the insoluble one, for both PML
and PML-3K (Fig. 4, b and c, and data not shown). Using a
more stringent criteria of nuclear matrix association (nu-
clear matrix preparations in situ; reference 35), we demon-
strate that the PML-3K mutant localized to the nuclear ma-
trix even before As2O3 exposure and is further shifted to
the matrix after As2O3 treatment (Fig. 4 d). Therefore,
PML binding to the nuclear matrix does not depend on
SUMO, and the failure of PML-3K to be degraded upon
As2O3 exposure is not the consequence of a defective ma-
trix transfer.
Since sumolation is not implicated in matrix association,
As2O3 could target PML to the matrix by modulating its
phosphorylation. To test this hypothesis, PML-3K–express-
ing cells were exposed to As2O3 with or without the phos-
phatase inhibitor okadaic acid. Remarkably, okadaic acid
could abrogate As2O3-induced matrix targeting of PML-
3K (Fig. 4 c), strongly suggesting that PML dephosphoryla-
tion controls its matrix association. Since PML sumolation
is influenced by its phosphorylation status (26, 36) As2O3
could control PML sumolation indirectly through its phos-
phorylation.
Figure 4. SUMO modifica-
tion of PML is dispensable for
PML matrix transfer induced by
As2O3. (a) CHO–PML were
treated with As2O3  for 1 h
(As1h), for 12 h (As), and/or
with lactacystin for 12 h (L and
L/As). Proteins were fractionated
into RIPA (R) or pellet (P) frac-
tions before Western blot analysis
(lanes are indicated). (b–d)
PML /  MEF stably transfected
wild-type PML or PML-3K mu-
tant were analyzed after a 1-h
As2O3  treatment. (b) Note the
As2O3-induced matrix transfer of
PML-3K. (c) As2O3-induced ma-
trix targeting of PML-3K is
blocked by pretreatment with
okadaic acid. Okadaic acid in-
duces an additional, likely a
phosphorylated, PML species. (d)
Immunofluorescence analysis of
in situ nuclear matrix preparation
from PML /  cells stably ex-
pressing wild-type PML or
PML-3K mutant. Note the
As2O3-induced aggregation of
NBs for PML, but not for the
PML-3K mutant, which remains
in distinctly smaller aggregates.1366 Sumolation in NB Formation and PML or PML/RAR  Degradation
Role of Sumolation in As2O-induced Changes in PML or
PML/RAR  Localization. Then we analyzed NB forma-
tion in cell lines stably expressing PML-3K in a CHO or
MEF(T)PML /  background. Compared with wild-type
PML, structures formed by PML-3K tend to be smaller and
heterogeneous in size but otherwise appear normal in their
number and distribution (Fig. 4 d). However, electron mi-
croscopic examination revealed a striking difference be-
tween the structures formed by PML and PML-3K. In the
absence of sumolation, NBs never appeared as empty
spheres with a PML-negative, electron light core (14), but
rather as dense aggregates dispersed through the nucleo-
plasm (Fig. 5). When cells expressing PML-3K were
treated with As2O3, no major qualitative change was ob-
served but the number of aggregates increased (Fig. 4 d).
This is in sharp contrast to structures formed by PML,
which upon As2O3 treatment become very large bodies
(Fig. 4 d) consisting of concentric circles of fibrillar material
(29). We conclude that while SUMO-1 modification is
dispensable for the formation of primary nuclear matrix ag-
gregates, it is required for the formation of mature NBs and
implicated in their morphological changes induced by
As2O3. When expressed in NIH3T3 cells, both PML/
RAR  and PML/RAR –K160R displayed the same mi-
crospeckled pattern (data not shown), demonstrating that
sumolation is not important for the localization of PML/
Figure 5. SUMO modification of PML is required for mature NBs
formation. Electronic microscopy examination of PML /  MEF stably
expressing PML (a) or PML-3K mutant (b). Note that small dense aggre-
gates are formed by PML-3K, whereas standard PML empty structures
where PML forms a distinct outer rim are observed upon expression of
wild-type PML (reference 14).
Figure 6. 11S proteasome is recruited by PML onto NBs. Confocal
analysis of PML and various proteasome components were realized on
PML overexpressing CHO treated for 1 h by As2O3 (As), lactacystin (L),
none ( ), or both (L/As). Localization of the endogenous 20S core and
11S , or   regulatory subunits of the proteasome are compared with that
of PML as indicated.1367 Lallemand-Breitenbach et al.
RAR . As expected, As2O3 exposure did not affect the lo-
calization of PML/RAR –K160R, whereas PML/RAR 
was shifted towards NBs.
PML Recruitment of the 11S Proteasome Complex Is SUMO
Dependent. Since As2O3-triggered PML degradation is
coupled to its NB targeting and appears to be proteasome
dependent, we analyzed the localization of the proteasome
in this setting. In CHO–PML cells, PML partially colo-
calized with the   and   subunits of 11S, the regulatory
complex of the proteasome (Fig. 6, and data not shown).
Strikingly, As2O3 or lactacystin greatly increased this colo-
calization on larger speckles, and lactacystin/As2O3 combi-
nation induced the formation of very large and bright
11S - and  -positive speckles (Fig. 6, and data not shown).
Colocalization of PML and the 20S core was observed in
rare cells only after As2O3 exposure (Fig. 6). In untrans-
fected CHO cells, little or no effect of these two drugs on
11S proteasome localization was observed (data not shown)
implying a direct role of PML to recruit this complex.
Then we examined the sumolation requirements for
proteasome recruitment onto NBs. Importantly, stably ex-
pressed PML-K160R failed to recruit the 11S proteasome
components upon As2O3 exposure, whereas PML-K490R
did (Fig. 7, and data not shown). This is consistent with the
requirement of the K160 conjugation site for As2O3-
induced degradation. As previously shown, PML-3K was
unable to recruit Daxx or Sp100 (19, 20), but both PML
and PML-3K similarly recruited CBP (Fig. 7).
Accumulation of PML fluorescence on nuclear dots
when As2O3-induced PML degradation was blocked by lac-
tacystin could suggest that degradation occurs on NBs. Sim-
ilarly, when NB4 APL cells were exposed to As2O3, RAR 
fluorescence was detected on NB-like structures and was
greatly enhanced by pretreatment with lactacystin (Fig. 8,
and data not shown). These observations imply that As2O3
triggered PML/RAR  degradation also occurs on NBs, in
contrast to that induced by RA (Fig. 8; reference 37). Al-
together, mature PML NBs appear to be the sites of PML
and PML/RAR  degradation, most likely through the
SUMO-dependent recruitment of proteasome components.
Discussion
Genesis of PML NBs. The dramatic effect of As2O3 to
recruit PML onto NBs lends considerable support to the
idea that most of PML is not NB bound (26, 29, 38). Con-
Figure 7. PML-3K still recruits CBP, but not Daxx or Sp100, while PML-K160R fails to recruit 11S  proteasome upon As2O3 exposure. Immuno-
fluorescences were performed on PML /  MEFs transiently transfected with wild-type PML or PML-3K mutant, stained with anti-PML, anti-Sp100,
anti-Daxx, and monoclonal anti-CBP antibodies (top). PML /  MEF cells infected with a PML or PML-K160R–expressing retrovirus were treated with
As2O3 for 1 h and stained with PML or anti-11S  antibodies as indicated (bottom). Note that 11S  does not colocalize with PML-K160R.1368 Sumolation in NB Formation and PML or PML/RAR  Degradation
trasting with previous proposals (26), we demonstrate that
PML targeting onto the nuclear matrix is not SUMO de-
pendent. Rather, PML traffic from the nucleoplasm to NBs
involves two distinct steps that can be separated by both
morphological and biochemical criteria: formation of pri-
mary nuclear matrix–associated bodies and NB maturation
(Fig. 9). The matrix targeting of PML or PML-3K is likely
regulated by a dephosphorylation event. PML dephos-
phorylation could trigger PML multimerization and promote
the formation of the primary aggregates. Two previous
studies had linked PML sumolation to its phosphorylation:
calyculin A, another phosphatase inhibitor, was shown to
block As2O3-triggered PML sumolation (26); and in the M
phase of the cell cycle, PML is specifically phosphorylated
and completely desumolated (36, and unpublished results).
The major difference between PML and PML–SUMO
bodies is their “apparent content” as detected by electron
microscopy. Interestingly, in mature PML NBs, PML
forms the outer shell and many proteins (Sp100, CBP) are
found within its electron clear core (39, and unpublished
results). Therefore, the SUMO-mediated maturation pro-
cess is coupled to the recruitment of interacting proteins
and their internalization. In conclusion, PML traffic from
the nucleoplasm to mature NBs involves two distinct steps:
an As2O3-triggered and phosphorylation-dependent aggre-
gation on the matrix, followed by a SUMO-dependent
maturation with protein recruitment (Fig. 9).
Molecular Determinants of PML and PML/RAR  Degrada-
tion. Of the three putative SUMO binding sites, only two
(K160 and K490) fit the (I/L)KXE consensus (25). These
two sites are independent and appear not to play similar
roles. Sumolation of K490 may play a role in PML nuclear
import, while K160 controls 11S    proteasome recruit-
ment and As2O3-induced PML degradation. Sumolation of
K160, but not K490, triggers a set of covalent modifica-
tions that yields high molecular weight PML complexes
whose presence is consistently associated with PML degra-
dation. Several hypotheses can be put forward as to the
mechanism of degradation. Either catabolism is the direct
consequence of K160 sumolation or competition exists be-
tween SUMO and ubiquitin for this site. Under this last
hypothesis, unsumolated PML would be the target for deg-
radation, which could be consistent with its stabilization by
lactacystin (Fig. 1 b). Yet, the kinetics of PML degradation
do not favor this model because massive sumolation pre-
cedes degradation (Figs. 1, 3, and 4). Sumolation of K160
may also trigger PML ubiquitination elsewhere, but our at-
tempts to identify ubiquitin in PML–SUMO complexes
have been repeatedly unsuccessful. The transient presence
of 20S and the accumulation of PML or PML/RAR  on
NBs upon As2O3/lactacystin exposure, as well as the failure
of PML-K160R to recruit the proteasome and be de-
graded, are all consistent with the idea that degradation oc-
curs on mature NBs. Altogether, our data provide the first
example where sumolation directly or indirectly promotes
protein degradation in a defined subnuclear compartment.
All PML isoforms are degraded in response to As2O3, yet
their common moiety is not. With the restriction that the
latter is consistently expressed at higher levels than the full-
size isoforms and might saturate a rate-limiting degradation
pathway, we conclude that isoform-specific sequences con-
vey sensitivity to As2O3. Some well-characterized domains
have been identified in the COOH terminus of RBCC
proteins (such as the PHD/TTC or bromodomain in TIF1
or the butyrophylin domain in RFP), which are lost in on-
cogenic fusions. Therefore, ability to promote PML degra-
dation in the presence of As2O3 constitutes the first com-
mon property of these regions. In PML/RAR , the
RAR  moiety, which was shown to specifically bind a 19S
proteasome component SUG-1 (40), may substitute for
the PML COOH termini to confer sensitivity to As2O3-
induced degradation.
Figure 8. As2O3 targets PML/RAR  onto NBs during As2O3-induced
but not RA-induced degradation. NB4 cells were exposed to 1  M
As2O3 or RA for 6 and 24 h, respectively, before immunofluorescence, as
indicated.
Figure 9. Schematic representation of PML traffic onto NBs. Under
our working model, PML is initially dispersed in the nucleoplasm possi-
bly in the chromatin. A specific dephosphorylation event triggered by
As2O3 targets PML to the nuclear matrix on primary PML bodies. Sumo-
lation then induces the maturation to secondary PML bodies that contain
the 11S proteasome subunits   and  , Daxx, and Sp100, where PML
would be degraded.1369 Lallemand-Breitenbach et al.
PML/RAR  degradations induced by As2O3 or RA,
while both proteasome dependent, have distinct mecha-
nisms. RA-induced degradation is dependent on RAR 
AF2, occurs on microspeckles (Fig. 8; reference 37), and
likely is a postactivation mechanism (34). Arsenic-induced
PML/RAR  degradation is SUMO dependent, occurs on
NBs, and is a very early effect. Since As2O3, in contrast to
RA, does not activate transcription through PML/RAR ,
degradation of the fusion protein could account for its ther-
apeutic effect. Therefore, it would be most interesting to
test both the leukemogenic potential of PML/RAR -
K160R and a putative response to As2O3.
Are NBs General Sites of Intranuclear Proteolysis? RING
finger proteins are proposed to act as E3 ubiquitin ligases
and hence participate in protein degradation (2). Mature
NBs whose formation is dependent on a RING-containing
protein, namely PML, and interact with a proteasome com-
plex, could be sites of protein degradation. The function of
the 11S complex is ill-understood. It seems to play a role
both in feeding the 20S proteasome core–misfolded proteins
for degradation in a ubiquitin-independent manner and in
proteolysis before MHC presentation. A role of the 11S  
complex in Hsp90-dependent protein refolding was also
proposed (41). Through either of these functions, the 11S
complex could play a role in the recruitment of the NB-
associated proteins and account for their number and sur-
prising variety. Sumolation of PML induces proteasome re-
cruitment. In that respect, the function of several proteins
involved in degradation complexes is enhanced when they
become modified by SUMO or Nedd8 (42).
The   and   components of the 11S complex are, like
PML and several NB-associated proteins, direct transcrip-
tional targets of IFN- . A link between immunoprotea-
some and PML NBs has very recently been proposed (43).
In that sense, the highest levels of PML expression are
found in macrophages, cells specialized in antigen presenta-
tion (15, 44). A chimeric protein known to be misfolded
has been shown to accumulate in PML NBs in a lactacys-
tin-dependent manner and after lactacystin retrieval, the
cleaved peptides became exposed on the MHC (45). That a
PML mutant suppresses CTL-dependent tumor rejection
(46) and PML /  animals show an immune defect (4)
could all be consistent with a functional relation between
PML and antigen presentation.
A number of transcription factors can be targeted onto
NBs upon PML expression. CBP could mediate recruit-
ment of these factors onto NBs, possibly through tripartite
CBP/PML/X complexes. Like MDM2, which uses CBP
to target p53 for degradation (47), PML and CBP could
cooperate to enhance both transcription and catabolism.
Similarly, the immediate early HSV-1 ICP0 gene localizes
to NBs, enhances transcription, and induces proteasome-
dependent degradation of specific cellular proteins (48–50),
providing another intriguing association between NBs,
proteolysis, and transcriptional activation.
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